Open AccessA Tumor-Agnostic NTRK (TRK) Inhibitor
Author(s) -
Franklin W. Huang,
Felix Y. Feng
Publication year - 2019
Publication title -
cell
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 26.304
H-Index - 776
eISSN - 1097-4172
pISSN - 0092-8674
DOI - 10.1016/j.cell.2019.02.049
Subject(s) - biology , trk receptor , bench to bedside , small molecule , kinase , computational biology , cancer research , download , bioinformatics , genetics , receptor , world wide web , computer science , physics , medical physics , neurotrophin
Larotrectinib is a small-molecule kinase inhibitor that targets NTRK fusions that occur in multiple types of cancer. Its FDA approval represents the first instance of a treatment indication being designated "tumor-agnostic" from the outset, being based on actionable genomic insights. To view this Bench to Bedside, open or download the PDF.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom